Metastatic squamous non-small cell lung cancer: Complete response following desmocollin-3 targeting immunotherapy as a monotherapy: A case report

---

Case Report

Author Details : Javvid Muzamil, Rudri Modi*

Volume : 11, Issue : 3, Year : 2024

Article Page : 333-335

https://doi.org/10.18231/j.ijpo.2024.073

Suggest article by email

Get Permission

---

Abstract

Non-small cell lung cancer (NSCLC) constitutes the majority of lung cancer cases. Among them, about one-third of the cases are of the squamous cell subtype and are associated with a poor prognosis compared to non-squamous NSCLC. Immunotherapy in the form of checkpoint inhibitors targeting the cell surface receptor PD-1, i.e. pembrolizumab plays a pivotal role in the treatment of advanced squamous NSCLC in the absence of the driver mutation and has become one of the first-line therapies. However, in patients with negative expression of PD-L1 and poor performance status, no optimal therapeutic strategy has been defined. A heat-killed Mycobacterium w (Mw) is a potent Toll-like receptor-2 (TLR-2) agonist, which induces a cell-mediated immune response targeting cancer cells expressing Desmocollin-3 (DSC3). Mw has been approved in India for the treatment of advanced NSCLC along with chemotherapy. Mw has shown maximum benefit in patients with squamous NSCLC without any added systemic toxicity. We present the case of a 65-year-old patient with PD-L1 negative and DSC3 positive metastatic Squamous NSCLC achieving a durable and complete response after monotherapy with heat-killed Mw.
 

Keywords: Programmed cell death ligand­ 1, Mycobacterium w, Desmocollin- 3, Monotherapy, Pembrolizumab, Durable response.

How to cite : Muzamil J, Modi R, Metastatic squamous non-small cell lung cancer: Complete response following desmocollin-3 targeting immunotherapy as a monotherapy: A case report. Indian J Pathol Oncol 2024;11(3):333-335

This is an Open Access (OA) journal, and articles are distributed under the terms of the Creative Commons Attribution-NonCommercial-ShareAlike 4.0 License, which allows others to remix, tweak, and build upon the work non-commercially, as long as appropriate credit is given and the new creations are licensed under the identical terms.